ALK and neuroblastoma: At present, constitutive ALK activation through mutation or amplification is the most accessible target for precision medicine in NB [7,8,9,10,11] with a recently initiated clinical trial for the 3rd generation ALK inhibitor Lorlatinib [51,52,53].